Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib plus docetaxel/carboplatin versus placebo plus docetaxel/carboplatin in advanced non-small cell lung cancer
NL-OMON23374Phase 3Active, not recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Jul 2003
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Docetaxel + carboplatin + placebo with Docetaxel + carboplatin + celecoxib (2 arms). Primary endpoints: Tumor response and Overall survival. Started Jul 2003; status: active, not recruiting.
02
Drugs
celecoxib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON23374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23374.